| Pronunciation |
 (DA
pi pray
zole) |
 |
| U.S. Brand Names |
| Rev-Eyes™ |
|
| Generic Available |
|
No |
|
| Synonyms |
| Dapiprazole Hydrochloride |
|
| Pharmacological Index |
|
Alpha1 Blocker, Ophthalmic |
|
| Use |
|
Reverse dilation due to drugs (adrenergic or parasympathomimetic) after eye exams |
|
| Pregnancy Risk Factor |
|
B |
|
| Contraindications |
|
Contraindicated in the presence of conditions where miosis is unacceptable, such as acute iritis and in patients with a history of hypersensitivity to any component of the formulation |
|
| Warnings/Precautions |
|
For ophthalmic use only |
|
| Adverse Reactions |
|
>10%: Central nervous system: Headache Ocular: Conjunctival injection, burning and itching eyes, lid edema, ptosis, lid erythema, chemosis, punctate keratitis, corneal edema, photophobia 1% to 10%: Ocular: Dry eyes, blurring of vision, tearing of eye |
|
| Drug Interactions |
|
No data reported |
|
| Stability |
|
After reconstitution, drops are stable at room temperature for 21 days. Store at room temperature (15°C to 30°C/59°F to 86°F) |
|
| Mechanism of Action |
|
Dapiprazole is a selective alpha-adrenergic blocking agent, exerting effects primarily on alpha1-adrenoceptors. It induces miosis via relaxation of the smooth dilator (radial) muscle of the iris, which causes pupillary constriction. It is devoid of cholinergic effects. Dapiprazole also partially reverses the cycloplegia induced with parasympatholytic agents such as tropicamide. Although the drug has no significant effect on the ciliary muscle per se, it may increase accommodative amplitude, therefore relieving the symptoms of paralysis of accommodation. |
|
| Usual Dosage |
|
Adults: Administer 2 drops followed 5 minutes later by an additional 2 drops applied to the conjunctiva of each eye; should not be used more frequently than once a week in the same patient |
|
| Administration |
|
Shake container for several minutes to ensure mixing. Instill 2 drops into the conjunctiva of each eye followed 5 minutes later by an additional 2 drops. Administer after the ophthalmic examination to reverse the diagnostic mydriasis. |
|
| Mental Health: Effects on Mental Status |
|
None reported |
|
| Mental Health: Effects on Psychiatric Treatment |
|
None reported |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Patient Information |
|
May still be sensitive to sunlight and sensitivity may return in 2 or more hours: exercise caution when driving at night or performing other activities in poor illumination. To avoid contamination, do not touch tip of container to any surface. |
|
| Nursing Implications |
|
Finger pressure should be applied to lacrimal sac for 1-2 minutes after instillation to decrease risk of absorption and systemic reactions |
|
| Dosage Forms |
|
Powder, lyophilized, as hydrochloride: 25 mg [0.5% solution when mixed with supplied diluent] |
|
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
